# First in Human Study of a Monoclonal Antibody (SOL-116) Targeting BSSL (Bile Salt-Stimulated Lipase), Single and Multiple Dose Parts

> **NCT05576012** · PHASE1 · COMPLETED · sponsor: **Lipum AB** · enrollment: 56 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** SOL-116
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05576012
- **Lead sponsor:** Lipum AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-13
- **Primary completion:** 2024-11-28
- **Final completion:** 2024-11-28
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2026-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05576012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05576012, "First in Human Study of a Monoclonal Antibody (SOL-116) Targeting BSSL (Bile Salt-Stimulated Lipase), Single and Multiple Dose Parts". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05576012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*